Somatic Mutations in Ovarian Cancer: Why They Matter for Treatment

Somatic mutations in ovarian cancer are one of the most important yet most underexplained pieces of the genetic puzzle. If you or someone you love has been diagnosed, or if you’re trying to understand your test results, this article is for you.

Not all mutations are the same. And not all genetic testing looks for the same thing.

Germline vs. Somatic: What’s the Difference?

Before going further, it helps to know that there are two broad categories of cancer-related mutations: germline and somatic.

Germline mutations in ovarian cancer are inherited. They’re present in every cell of your body from birth and can be passed down to your children. (Learn more: “Germline Mutations in Ovarian Cancer: Understanding Genetic Risk and Testing”)

Somatic mutations are different. They’re not inherited. They develop over time, within specific cells. In the context of ovarian cancer, they occur in tumor cells themselves. You weren’t born with them. They can’t be passed to your children. And they won’t show up in a standard blood-based genetic test — though specialized liquid biopsy assays can sometimes detect somatic mutations through circulating tumor DNA (ctDNA) in the blood, which is different from routine genetic testing.

This distinction matters a great deal, both for understanding your personal cancer risk and for choosing the most effective treatment.

What Are Somatic Mutations in Ovarian Cancer?

Somatic mutations are acquired genetic changes that develop within tumor cells over time. They’re not present in normal tissue — only in the cancer. Unlike germline mutations, they arise spontaneously, driven by factors like DNA replication errors, aging, environmental exposures, or cellular stress.

Think of it this way: germline mutations are the genetic hand you were dealt. Somatic mutations are changes the cancer acquires as it grows.

In ovarian cancer, somatic mutations affect genes that regulate DNA repair, cell division, tumor suppression, and signaling pathways. The specific mutations present in a tumor tell oncologists a great deal about how the cancer is likely to behave, and which treatments are most likely to work.

The Most Common Ovarian Cancer Somatic Mutations

Every ovarian cancer tumor is genetically unique. But certain somatic mutations show up again and again across patients, and researchers have mapped them carefully enough that we now know which ones are most likely to influence treatment response, prognosis, and clinical outcomes. 

Here are the most clinically significant ones.

KRAS, NRAS, and BRAF: Mutations More Common in LGSOC

Low-grade serous ovarian cancer (LGSOC) has a distinct somatic mutation profile compared to the high-grade form. KRAS mutations are found in approximately 25% of LGSOC cases, BRAF in around 8%, and NRAS in roughly 8% as well.  

These MAPK pathway mutations are central to LGSOC biology, and they’ve driven the development of targeted therapies now being investigated for this subtype. This includes MEK inhibitors like trametinib and the recently groundbreaking avutometinib and defactinib combination. If you want to understand why LGSOC responds differently to standard chemotherapy, these mutations are a big part of the answer.

Somatic BRCA1 and BRCA2 Mutations

Somatic BRCA1/2 mutations occur in roughly 5 to 7% of ovarian cancers. These are distinct from germline BRCA mutations. They arise in tumor tissue, not in normal cells, and they’re not hereditary.

The ORZORA trial found median progression-free survival of 16.6 months in somatic BRCA patients on maintenance olaparib, versus 19.3 months in germline BRCA patients. This is one of the strongest arguments for routine somatic tumor testing in all ovarian cancer patients.

TP53: The Near-Universal Mutation (for HGSOC)

TP53 is the most frequently identified somatic mutation in ovarian cancer. In high-grade serous ovarian cancer (HGSOC), TP53 mutations are present in up to 96% of tumors. 

TP53 encodes the p53 protein, which functions as a critical tumor suppressor. It tells damaged cells to stop dividing or to self-destruct. When TP53 is mutated, that checkpoint fails. Cells keep growing when they shouldn’t, and the damage goes further than uncontrolled division. 

p53 also regulates DNA repair, antioxidant defense, and inflammatory signaling in the tumor microenvironment. In the fallopian tube epithelium, where many ovarian cancers are thought to originate, TP53 mutations disrupt antioxidant defenses, allowing DNA damage to accumulate and genetic instability to take hold.

Multiple studies confirm this pattern. One study found TP53 somatic mutations in 66.4% of patients overall, and in 72% of those with the high-grade serous subtype. Another study found TP53 mutations in 68% of HGSOC patients analyzed by next-generation sequencing.

TP53 mutation is so consistent in HGSOC that its presence is often used as a molecular marker to confirm the diagnosis.

For years, TP53 mutations were considered essentially undruggable. That may be changing. A first-in-class oral TP53 reactivator is now in Phase II investigation — the PYNNACLE trial — targeting metastatic or locally advanced solid tumors carrying the TP53 Y220C mutation. 

The drug works by binding to the mutated p53 protein and reshaping it back toward its normal, functional conformation, effectively attempting to restore the tumor-suppressing activity that the mutation disabled. It’s an early but genuinely promising development in a space where therapeutic options have historically been limited.

Homologous Recombination Repair (HRR) Genes

Beyond BRCA, a broader set of genes involved in homologous recombination repair (HRR) can also carry somatic mutations in ovarian cancer tumor tissue. When these genes are mutated, cells lose the ability to accurately repair DNA double-strand breaks, forcing them to rely on error-prone repair pathways that drive further genetic instability and tumor progression.

One study found that mutations in non-BRCA HRR genes may actually be associated with even more favorable survival outcomes than BRCA1 mutations specifically. The survival advantage in that non-BRCA HRR group was marked: a finding that highlights how important broader genetic profiling has become.

PIK3CA and the PI3K/AKT Pathway

PIK3CA somatic mutations are rare in high-grade serous ovarian cancer, appearing in roughly 2 to 4% of HGSOC cases. However, PIK3CA amplifications — a distinct mechanism from point mutations — are considerably more common, occurring in approximately 10 to 20% of HGSOC. Broader activation of the PI3K/AKT pathway is seen in around 50% of HGSOC cases, making it one of the more frequently dysregulated signaling networks in this subtype. 

PIK3CA mutations are far more prevalent in other subtypes, appearing in up to 40 to 50% of clear cell and endometrioid ovarian cancers, and account for roughly 12% of all ovarian cancer cases when subtypes are combined. This pathway plays a central role in driving cell growth and survival, and its frequent activation (through multiple mechanisms) has made it an active area of therapeutic research.

RB1 and NF1

Somatic mutations in RB1 and NF1 are also recurrently identified in HGSOC, typically in the 2 to 6% range for point mutations, though deletions increase these frequencies substantially.

RB1 encodes the retinoblastoma protein, which normally controls the G1/S cell cycle checkpoint by inhibiting E2F transcription factors, keeping cell division in check. When RB1 is mutated, that brake is lost and the cell cycle advances unchecked. 

NF1 encodes neurofibromin, a RAS GTPase-activating protein that downregulates the RAS/RAF/MAPK signaling pathway. A loss-of-function mutation in NF1 therefore promotes cell proliferation through the same signaling axis implicated in KRAS and BRAF mutations,  meaning its functional consequences overlap significantly with the MAPK pathway alterations more commonly associated with LGSOC.

ARID1A and Endometriosis-Associated Subtypes

ARID1A somatic mutations are found in roughly 40 to 67% of clear cell ovarian cancers and 30% of endometrioid ovarian cancers: two rare ovarian cancer subtypes that often arise in the context of endometriosis. 

ARID1A is a tumor suppressor gene with roles in transcriptional regulation, cell cycle control, and DNA double-strand break repair. When it’s mutated, all three of those functions are compromised, creating conditions that favor tumor development and progression. 

If you’ve been navigating the overlap between endometriosis and ovarian cancer, ARID1A is one of the molecular links researchers are studying closely.

Somatic Mutations and Treatment Decisions

This is where ovarian cancer somatic mutations move from interesting to essential.

Knowing the somatic mutation profile of a tumor isn’t just academic. It directly informs which therapies are most likely to work. Sometimes, it unlocks access to treatments a patient might otherwise not receive.

PARP inhibitors are the clearest example. Drugs like olaparib, niraparib, and rucaparib are approved for ovarian cancer patients with BRCA mutations. That includes both germline and somatic BRCA mutations. 

If only germline testing is performed and it comes back negative, a somatic BRCA mutation could be missed entirely. That’s a missed treatment opportunity.

Platinum-based chemotherapy sensitivity is also linked to HRR mutation status. Multiple studies confirm that patients with BRCA or other HRR mutations, (whether germline or somatic) show higher rates of platinum sensitivity and improved overall survival compared to patients with HRR-wildtype tumors.

Immunotherapy for ovarian cancer may also be relevant for certain patients. Mismatch repair (MMR) gene mutations (found in a subset of ovarian cancers, particularly endometrioid) can lead to microsatellite instability (MSI), which predicts response to immune checkpoint inhibitors.  

Targeted therapies for LGSOC (including MEK inhibitors and combination regimens) are guided by KRAS, NRAS, and BRAF somatic mutation status. This is an active and rapidly evolving research area.  

How Is Somatic Testing Different from Germline Testing?

Somatic testing is done on tumor tissue, taken from a biopsy or surgical specimen. It identifies mutations that exist only in cancer cells. 

Germline testing is done on normal tissue, usually blood or saliva. It identifies inherited mutations present in every cell of your body. 

A third option — circulating tumor DNA (ctDNA) testing — analyzes DNA shed by tumor cells into the bloodstream. Because ctDNA has a short half-life, it offers a snapshot of tumor biology at a given moment in time rather than a comprehensive profile, and it’s most commonly used when tumor tissue isn’t available. It’s also showing promise as a surveillance tool: one study found that ctDNA detected recurrence earlier than CA-125, the standard blood marker currently used to monitor for returning disease.

Somatic testing is especially relevant for LGSOC patients. Because LGSOC has a naturally low tumor mutation burden and grows slowly, it sheds very little DNA into the bloodstream. Research from the RAMP-201 clinical trial found that blood-based testing missed KRAS mutations in more than half of LGSOC patients (56%) who were confirmed to carry them in tumor tissue.

Put simply: if you have LGSOC and only blood-based testing is done, critical somatic mutations may not show up. Tumor tissue testing is the standard for a reason.

According to both NCCN and ASCO guidelines, all patients diagnosed with epithelial ovarian cancer should receive both germline and somatic genetic testing. Both results can influence treatment decisions.

It’s also worth knowing that testing doesn’t stop at diagnosis; at each recurrence, tumor tissue should be tested for biomarkers that weren’t previously evaluated, since a tumor’s molecular profile can shift over time.

Whether retesting the same biomarkers at every recurrence adds clinical value is still an evolving area of evidence. What’s most important is discussing with your medical team which biomarkers to test for at each stage of your disease, because the landscape of clinically relevant mutations continues to expand, and something that wasn’t actionable at diagnosis may be by the time a recurrence occurs.

Understanding Your Somatic Test Results

Results from tumor testing follow a tiered classification system that’s distinct from germline reporting. Where germline results focus on pathogenicity (ranging from pathogenic to benign), somatic results are organized around clinical actionability:

Tier I — Strong clinical significance: Variants with well-established clinical relevance, including actionable mutations with FDA-approved or standard-of-care treatment implications.

Tier II — Potential clinical significance: Mutations that show promise in clinical trials or are supported by biological evidence, but haven’t yet reached standard-of-care status. These may still open doors to trial eligibility or inform treatment thinking.

Tier III — Variants of unknown significance (VUS): A change was detected, but there isn’t yet enough evidence to determine its clinical impact. This is more common than people expect, and it can feel frustrating to receive. 

The science is evolving, though; ask your oncologist or genetic counselor what a VUS result means in your specific situation, and whether it warrants monitoring as new evidence emerges.

Who Should Have Somatic Tumor Testing?

The short answer: anyone diagnosed with epithelial ovarian cancer.

NCCN guidelines specify that both germline and somatic testing should be performed for patients diagnosed with ovarian, fallopian tube, or primary peritoneal cancers. This applies regardless of age, family history, or germline test results.

If you haven’t had tumor testing yet, ask your gynecologic oncologist about it. The information it provides — on BRCA status, HRD, MSI, and other mutation profiles — can shape every major treatment decision that follows.

The Bottom Line on Somatic Mutations in Ovarian Cancer

Ovarian cancer somatic mutations are not a footnote in your diagnosis. They’re a core part of understanding your disease and figuring out how to treat it.

Testing for these mutations guides treatment decisions in real, meaningful ways, from PARP inhibitor eligibility to platinum sensitivity to emerging targeted therapies. And in LGSOC specifically, somatic mutation profiling is increasingly central to the search for new treatment options.

If you’ve been diagnosed with ovarian cancer and haven’t had comprehensive somatic tumor testing, ask your care team. You deserve the full picture.